A preliminary AHA survey analysis links recent cannabis use with cardiovascular history. What the findings can—and cannot—tell consumers.
The physicians’ organization wants botanical products evaluated through rigorous evidence as FDA gathers feedback on research, manufacturing and regulatory challenges.
Airo and SOMAÍ announce four inhalation formulations with IPS Pharma distribution. Patient access still depends on prescribing and pharmacy supply.
New transfers must meet HB 4454, while OMMA allows qualifying existing dispensary inventory to remain. The distinction matters for operators and patients.
A small University of Auckland study will compare a cannabis oil with placebo over months, separating an important research question from claims of proven benefit.
Health Canada recalled one OVERTIME Punch Out dried-flower lot after THC and CBD values were switched on its label. Ontario purchasers should check the lot number.
Bloomwell’s survey finds patients prefer pharmacy cannabis access, but its voluntary sample and commercial source limit what the findings can establish.